Do Eyelash Growth Serums Work? Latisse vs OTC Prostaglandin Serums and the Eye Risks

Long, dense eyelashes are a central cosmetic goal for many consumers. The market has responded with a wide array of eyelash growth serums, ranging from prescription-only options to mass-market drugstore formulations. While these products promise rapid lash enhancement, the pharmacological mechanisms that drive hair follicle growth also carry significant ocular and periorbital side effects.

The only eyelash-growth product FDA-approved for inadequate lashes (hypotrichosis) is Latisse (bimatoprost 0.03 percent), a prescription prostaglandin analog approved in 2008 that extends the lash growth phase; full effect takes about 16 weeks of nightly use and reverses when you stop. Most drugstore lash serums rely on a different prostaglandin analog, isopropyl cloprostenate, which the FDA considers an unapproved drug (it is not FDA-approved for lash growth) and which carries the same class risks: permanent iris darkening, eyelid pigmentation, and orbital-fat loss or sunken eyes. Peptide and botanical serums are gentler but have little rigorous growth evidence.

Evaluating eyelash growth serums requires analyzing the underlying pharmacology of prostaglandin analogs, the regulatory divisions between drugs and cosmetics, and the clinical evidence supporting active ingredients.

---

Latisse (Bimatoprost): The Only FDA-Approved Lash-Growth Drug

To understand how eyelash growth serums function, it is necessary to examine the only product that has successfully navigated the FDA’s New Drug Application (NDA) approval pathway for this indication.

The Origin: From Glaucoma to Hypotrichosis

Bimatoprost was originally developed and approved in 2001 as Lumigan, an ophthalmic drop designed to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. During clinical trials, researchers observed a consistent side effect: patients developed longer, thicker, and darker eyelashes.

Allergan (the manufacturer) subsequently conducted clinical trials evaluating a topical formulation applied to the eyelid margin rather than directly into the eye. In December 2008, the FDA approved Latisse (bimatoprost ophthalmic solution 0.03%, NDA 022369) for the treatment of eyelash hypotrichosis (inadequate or sparse eyelashes).

The Growth Mechanism: How Anagen is Extended

Eyelashes, like all human hair, progress through a continuous three-phase growth cycle:

1. Anagen Phase (Active Growth): Typically lasts 1 to 2 months for eyelashes.
2. Catagen Phase (Transition): Lasts 2 to 3 weeks, where the follicle shrinks.
3. Telogen Phase (Resting/Shedding): Lasts 4 to 9 months before the hair falls out.

Prostaglandin analogs like bimatoprost act as synthetic agonists for the prostamide receptor. In the hair follicle, bimatoprost stimulates the transition of follicles from the telogen phase into the anagen phase. Simultaneously, it prolongs the duration of the anagen phase itself.

By keeping the eyelash follicle in the active growth phase for an extended period, the hair grows longer than its natural baseline. Additionally, bimatoprost stimulates melanogenesis (melanin production) in the hair bulb, resulting in darker lashes, and increases the size of the dermal papilla, yielding thicker shafts. For a parallel look at hair growth biology and phase management on the scalp, see our clinical review on how anagen-phase actives grow hair and lashes.

Clinical Efficacy: The 16-Week Timeline

The clinical trials supporting the approval of Latisse evaluated 278 adult patients over a 16-week period:

• By week 8, patients began to notice a statistically significant difference in lash length and thickness.
• By week 16, the treatment group demonstrated a 25% increase in lash length, a 106% increase in thickness/fullness, and an 18% increase in lash darkness.
• The Reversibility Clause: Prostaglandin-induced lash growth is not permanent. Once application stops, the hair follicle cycle resets over several weeks to months, and the eyelashes gradually return to their pre-treatment appearance as the treated lashes naturally shed.

---

Chemistry of Prostaglandin Analogs: Bimatoprost vs. Isopropyl Cloprostenate

To understand how over-the-counter serums replicate the growth effects of Latisse, one must analyze the chemical structures of these active molecules.

Chemical Class Structure & Receptor Activity:
Bimatoprost:             Prostamide Agonist  =======> High Efficacy & Active Side Effects
Isopropyl Cloprostenate: Synthetic PGA       =======> High Dermal Penetration & Active Side Effects

1. Bimatoprost (Prescription)

• Structure: An ethyl amide derivative of prostaglandin F2-alpha (PFF2a). Technically classified as a prostamide.
• Action: Bimatoprost has low affinity for the classical FP prostaglandin receptor. Instead, it targets a unique prostamide receptor system. It is highly hydrophilic, meaning it does not penetrate intact skin easily, which is why it must be applied precisely to the lash line to avoid systemic absorption.

2. Isopropyl Cloprostenate (OTC)

• Structure: A synthetic prostaglandin F2-alpha analog containing an isopropyl ester group.
• Action: The isopropyl ester modification makes the molecule highly lipophilic (fat-soluble). This lipophilicity allows it to cross the epidermal skin barrier of the eyelid much more efficiently than bimatoprost.
• Receptor Activity: Once absorbed, local esterases cleave the isopropyl group, releasing the active cloprostenol acid, which acts as a highly potent agonist at the FP prostaglandin receptor. In simple terms, it is a highly active drug that penetrates the skin surface more easily than the prescription equivalent, raising the risk of local fat tissue atrophy.

---

OTC Prostaglandin Serums (Isopropyl Cloprostenate): Unapproved Drugs

Following the commercial success of Latisse, cosmetic companies sought to offer similar lash-growth results over the counter, bypassing the prescription requirement. To do this, they formulated cosmetic serums with synthetic prostaglandin analogs (PGAs) that are structurally related to bimatoprost.

The Regulatory Bypass

Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), the distinction between a drug and a cosmetic is defined by its intended use:

• Cosmetics are defined as articles intended to be rubbed, poured, sprinkled, or sprayed on the body for cleansing, beautifying, promoting attractiveness, or altering the appearance.
• Drugs are defined as articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, or intended to affect the structure or any function of the body.

Because eyelash hypotrichosis is a medical condition, and changing the physiological growth cycle of a hair follicle is a structural alteration of the body, any product containing active ingredients that grow lashes is technically operating as a drug.

By labeling their products as "cosmetic conditioning serums" and avoiding explicit medical claims, manufacturers of OTC prostaglandin serums attempted to bypass the required clinical testing and safety oversight required for FDA drug approval.

The FDA Stance: The 2011 Lifetech Warning Letter

The FDA has actively challenged this regulatory bypass. In April 2011, the FDA issued a landmark Warning Letter to Lifetech Resources, the manufacturer of RapidLash and other private-label lash serums containing isopropyl cloprostenate.

The FDA stated that:

1. The presence of isopropyl cloprostenate (a prostaglandin analog) makes the products unapproved new drugs and misbranded drugs under federal law.
2. Prostaglandin analogs are known to affect the structure of the body (hair follicles) and carry significant ophthalmic safety risks.
3. Because these products are sold directly to consumers without medical supervision or prescription packaging, they bypass the required warning labels and safety disclosures.

Since 2011, the FDA has continued to issue warning letters to cosmetics manufacturers (including a series of warnings in 2023 and 2024 targeting unapproved ophthalmic and eyelid topicals) reiterating that synthetic prostaglandin analogs cannot be sold as over-the-counter cosmetics. However, due to the sheer size of the cosmetics market and limited enforcement resources, many brands continue to formulate with isopropyl cloprostenate, often masking it under complex chemical names in ingredient lists.

---

The Real Eye Risks: Prostaglandin-Associated Side Effects

Because synthetic prostaglandin analogs share the same biological pathways as prescription bimatoprost, they also share the same adverse event profile. When applied to the eyelid margin, these active molecules migrate into the eye and surrounding tissues, resulting in several well-documented side effects.

1. Prostaglandin-Associated Periorbitopathy (PAP)

The most significant long-term cosmetic side effect of eyelash serums is prostaglandin-associated periorbitopathy (PAP). Prostaglandin analogs inhibit adipogenesis (the formation of fat cells) and stimulate lipolysis (the breakdown of fat) in the preseptal and orbital fat pads surrounding the eye.

This orbital fat atrophy results in:

• Deepening of the upper eyelid sulcus: Creating a hollowed, "sunken eye" appearance.
• Eyelid Ptosis: Drooping of the upper eyelid.
• Enophthalmos: Retrodisplacement of the eyeball into the orbit.
• Exposure of the sclera: Making the eyes appear permanently tired or aged.

The Biochemical Pathway of PAP

Prostaglandins target FP receptors on local adipocytes (fat cells). When activated, this receptor initiates a signaling cascade that downregulates critical transcription factors:

• ZFP423: A key zinc-finger protein required to commit stem cells to the adipocyte lineage.
• PPAR-gamma (Peroxisome Proliferator-Activated Receptor Gamma): The master regulator of fat cell differentiation and lipid accumulation. By shutting down these pathways, the body can no longer replace aging fat cells in the orbit, leading to progressive, localized fat tissue atrophy. While some studies suggest that PAP can reverse after discontinuing the serum, clinical experience shows that in patients who have used prostaglandin lash serums for multiple years, the loss of orbital fat support is often permanent or only partially reversible.

2. Irreversible Iris Darkening (Melanogenesis)

Prostaglandin analogs stimulate melanin production in the melanocytes of the iris. In patients with mixed-colored eyes (such as hazel, green, or blue-brown), this can lead to a permanent increase in brown pigmentation, permanently changing the color of the eye.

This effect is irreversible. Once the iris pigment darkens, it does not return to its original shade after stopping the product. While this risk is lower when the serum is applied carefully to the lash line (where systemic absorption is minimized) compared to direct glaucoma eye drops, it remains a listed warning in the FDA Latisse label.

3. Eyelid Hyperpigmentation

Applying prostaglandin analogs to the skin surface stimulates melanogenesis in the epidermal cells of the eyelid, resulting in a dark purple or brown band along the upper lash line. This hyperpigmentation is usually reversible, fading slowly over several weeks to months after discontinuing the serum.

4. Meibomian Gland Dysfunction (MGD) and Dry Eye

Topical prostaglandins can trigger chronic inflammation of the meibomian glands, which line the edge of the eyelids. These glands secrete the lipid (oil) layer of the tear film, which prevents tears from evaporating too quickly.

• When prostaglandins block or damage these glands, the tear film loses its lipid layer, resulting in evaporative dry eye syndrome.
• Symptoms include chronic eye redness, a burning sensation, foreign-body sensation, and blurred vision. To see how these side effects are structured within a clinical prescribing document, refer to our analysis on how to read an FDA drug label's adverse events.

---

Application Protocol and Minimizing Exposure: The Clinician's Method

If a patient decides to use a prostaglandin-based eyelash growth serum, proper application technique is the single most effective way to reduce the risk of periorbital fat atrophy, iris darkening, and dry eye.

1. The Single-Drop, Micro-Brush Protocol

Many consumers apply lash serums in the same manner as eyeliner—drawing a thick, wet line across the lid. This results in significant excess product migrating directly into the eye or spreading onto the lower lid.

• The Applicator: Use a single-use, sterile micro-applicator brush (such as the ones supplied with Latisse). Avoid reusable bottle brushes, which accumulate bacteria over time.
• The Dose: Place exactly one drop of bimatoprost onto the horizontal surface of the applicator brush. This single drop is sufficient to treat both eyes.
• The Path: Draw the brush carefully along the skin of the upper eyelid margin at the base of the eyelashes. Do not apply directly to the eye, to the lower lash line, or inside the lower lid.
• The Dry Off: Immediately blot any excess solution that spreads beyond the lash line using a clean tissue. This minimizes contact with the surrounding skin, directly reducing the risk of eyelid hyperpigmentation and preseptal fat loss.

2. Contact Lens Management

Topical solutions like bimatoprost contain preservatives—specifically benzalkonium chloride (BAK). BAK is readily absorbed by soft contact lenses and can cause corneal irritation or lens discoloration.

• Contact lenses must be removed before applying the lash serum.
• Patients should wait at least 15 minutes after application before reinserting contact lenses.

---

Prostaglandin-Free Alternatives: Efficacy vs. Conditioning

Because of the periorbital fat loss and eye color risks associated with prostaglandins, many brands offer "prostaglandin-free" formulations. It is critical to distinguish between products that actively grow hair and those that merely condition it.

1. Peptide-Based Serums (The Keratin Boosters)

Peptide serums formulate with complexes like myristoyl pentapeptide-17 and biotinoyl tripeptide-1.

• The Claim: These peptides are marketed as being able to stimulate keratin genes, reinforcing the structural integrity of the hair shaft.
• The Science: Unlike prostaglandins, peptides do not interact with FP receptors and do not extend the duration of the anagen growth phase. They act as humectants and conditioning agents. By coating the lash shaft and keeping it flexible, they prevent the lash from breaking prematurely due to mascara application or makeup removal.
• The Result: The lashes appear fuller because fewer hairs are lost to mechanical breakage, but they do not grow longer than the patient's genetic ceiling. Review our guide on which cosmetic actives have evidence for an analysis of topical ingredient efficacy.

2. Castor Oil (Ricinus communis)

A common at-home remedy for eyelash growth is the application of pure castor oil.

• The Chemistry: Castor oil is composed of approximately 90% ricinoleic acid, a monounsaturated fatty acid.
• The Action: Ricinoleic acid has mild anti-inflammatory properties and acts as an occlusive humectant, locking moisture into the hair shaft. It does not contain any growth factors or prostaglandin analogs.
• The Result: Applying castor oil coats the lash shafts, making them reflect light better and appear temporarily thicker and darker. It does not alter the hair follicle cycle or stimulate new length.

---

Post-Treatment Recovery: Can Side Effects Be Reversed?

When a patient stops using a prostaglandin-based eyelash serum due to side effects, the recovery timeline varies by symptom:

1. Lash Length and Thickness: Return to baseline within 8 to 16 weeks. As the treated anagen lashes complete their cycle and shed, they are replaced by new lashes that have not been exposed to the drug.
2. Eyelid Skin Hyperpigmentation: Fades gradually. In most patients, the dark band along the lash line disappears within 2 to 6 months after stopping the product.
3. Conjunctival Redness and Dry Eye: Resolve quickly, usually within 1 to 2 weeks as meibomian gland inflammation subsides.
4. Prostaglandin-Associated Periorbitopathy (PAP): The hollowing of the eyes and loss of orbital fat pads show very limited reversibility. In patients who used the serum for less than 6 months, some fat volume may return over a year. In long-term users, the adipocyte differentiation pathway has been suppressed for too long, and the hollowing is often permanent, requiring surgical correction with micro-fat grafting or hyaluronic acid dermal fillers.
5. Iris Darkening: This is fully irreversible. Once the pigment cells of the iris produce excess melanin, the color change is permanent.

---

Efficacy and Safety Profile by Ingredient Class

Lash Serum Ingredient Comparison

---

Class Action Settlements and Global Regulation

The failure of cosmetic brands to disclose the presence of unapproved drug ingredients and their associated eye risks has resulted in significant legal and regulatory consequences.

1. The Rodan + Fields Lash Boost Settlement (2022)

In 2022, skincare giant Rodan + Fields agreed to a $38 million settlement to resolve a class-action lawsuit alleging that the company failed to disclose that its Lash Boost serum contained isopropyl cloprostenate and carried serious risks of eye irritation, iris color changes, and orbital fat loss. As part of the settlement, the company was required to add clear warning labels to the product packaging.

2. The Grande Cosmetics Settlement (2024)

In February 2024, Grande Cosmetics settled a class-action lawsuit for $6.25 million regarding its GrandeLash-MD serum. The lawsuit argued that the company marketed the serum as a safe cosmetic while omitting the safety risks of its active ingredient, isopropyl cloprostenate. The settlement highlighted the consumer-protection risks of selling active pharmacological agents under the guise of basic cosmetics.

3. International Restrictions: Health Canada and the European Union

Other regulatory jurisdictions have taken more decisive action than the United States:

• Health Canada: Classifies all products containing prostaglandin and its analogs (including isopropyl cloprostenate) as prescription drugs, effectively banning them from over-the-counter sale in cosmetics.
• European Commission: Under the EU Cosmetics Regulation, the Scientific Committee on Consumer Safety (SCCS) has repeatedly raised safety concerns regarding prostaglandin analogs in cosmetics, leading several European countries (such as Sweden and Austria) to pull OTC prostaglandin lash serums from retail shelves.

---

Clinical Exclusions: Who Should Avoid Prostaglandin Serums?

Ophthalmic safety protocols require that certain patients avoid the use of prostaglandin-based lash serums (both Latisse and OTC equivalents):

1. Glaucoma Patients Using PGA Eye Drops: Patients who are actively using glaucoma medications (such as Lumigan, Xalatan, or Travatan) must not use Latisse or OTC lash serums, as the cumulative dose of prostaglandins can alter the efficacy of their pressure-lowering medications and complicate clinical tracking.
2. History of Uveitis or Active Ocular Inflammation: Prostaglandins are inflammatory mediators; topical application can trigger a recurrence of intraocular inflammation (uveitis).
3. Active Eye Infections or Blepharitis: Eyelid inflammation can worsen with PGA application.
4. Dry Eye Syndrome: Prostaglandin use can exacerbate meibomian gland dysfunction, leading to severe dry eye symptoms.

---

FAQ

Can eyelash serum change my eye color?

Yes. Prostaglandin analogs—such as bimatoprost (in Latisse) and isopropyl cloprostenate (in many OTC serums)—can stimulate melanin production in the iris. This can permanently darken mixed-colored eyes (such as green, hazel, or blue-brown). While this is uncommon with careful application to the upper lash line, the change is permanent and cannot be reversed after stopping the serum. Prostaglandin-free peptide or botanical serums carry no risk of eye color changes.

Are over-the-counter lash serums FDA-approved?

No. The American Academy of Ophthalmology (AAO) and the FDA emphasize that Latisse (bimatoprost 0.03%) is the only FDA-approved product for eyelash growth. OTC serums that contain synthetic prostaglandin analogs like isopropyl cloprostenate are classified by the FDA as unapproved drugs. They bypass the strict safety, manufacturing, and clinical trials required for drug approval, and are sold without warning labels.

Can lash serums hollow or sunken my eyes?

Yes. Prostaglandin-associated periorbitopathy (PAP) is a recognized side effect of all prostaglandin analogs. The active ingredients penetrate the skin and cause fat cell atrophy in the surrounding preseptal and orbital fat pads. This creates a hollowed, sunken appearance and can lead to eyelid drooping (ptosis). While mild cases may improve after stopping the serum, long-term use can result in permanent loss of periorbital volume.

---

Sources

• U.S. Food and Drug Administration. "Latisse (bimatoprost ophthalmic solution) 0.03% Prescribing Information." FDA, 2021. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/022369s014lbl.pdf
• American Academy of Ophthalmology. "What You Should Know About Eyelash Growth Serums." AAO, 2026. https://www.aao.org/eye-health/tips-prevention/latisse
• Smith, S., et al. "Bimatoprost in the treatment of eyelash hypotrichosis: Clinical trial results and safety profile." PMC, 2010. https://pmc.ncbi.nlm.nih.gov/articles/PMC2861943
• U.S. Food and Drug Administration. "Warning Letters: Health Fraud Warnings Index." FDA, 2024. https://www.fda.gov/consumers/health-fraud-scams/2024-warning-letters-health-fraud
• Arnold & Porter. "Grande Cosmetics settles class-action lawsuit over isopropyl cloprostenate disclosure." Consumer Products and Retail Navigator, 2024. https://www.arnoldporter.com/en/perspectives/blogs/consumer-products-and-retail-navigator/2024/02/grande-cosmetics-false-advertising-settlement